SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.86M | 45.45M | -10.11M | -5.20M | -11.39M |
| Total Depreciation and Amortization | 763.30K | 765.50K | 774.50K | 778.30K | 785.70K |
| Total Amortization of Deferred Charges | 261.10K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.38M | -60.88M | 1.25M | -4.44M | 2.96M |
| Change in Net Operating Assets | -7.32M | 1.62M | 942.80K | 1.06M | -1.88M |
| Cash from Operations | -16.78M | -13.05M | -7.15M | -7.80M | -9.53M |
| Capital Expenditure | -933.20K | -- | -- | -- | -55.40K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 0.00 | 500.00 | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -773.00K | -129.87M | 5.20M | 4.67M | 9.39M |
| Cash from Investing | -1.71M | -129.87M | 5.20M | 4.67M | 9.33M |
| Total Debt Issued | -- | -- | -- | -- | 516.00K |
| Total Debt Repaid | -36.70K | -36.00K | -173.80K | -171.90K | -274.10K |
| Issuance of Common Stock | 0.00 | 168.73M | -- | -- | -- |
| Repurchase of Common Stock | -4.30K | -4.90K | 0.00 | -2.10K | -24.90K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -800.00 | -- | -- | -- | 0.00 |
| Cash from Financing | -41.70K | 168.69M | -173.80K | -174.00K | 217.00K |
| Foreign Exchange rate Adjustments | -397.90K | -37.50K | 179.40K | 42.50K | -288.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.92M | 25.73M | -1.95M | -3.26M | -273.20K |